Sangro B, Kudo M, Erinjeri JP, Qin S, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
PMID: 39798579